Apogee Therapeutics, Inc.
APGE
$68.50
$1.732.59%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.30% | 31.82% | 59.97% | 76.53% | 90.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.87% | 21.46% | 65.82% | 65.25% | 104.23% |
| Operating Income | -2.87% | -21.46% | -65.82% | -65.25% | -104.23% |
| Income Before Tax | -3.16% | -32.52% | -95.24% | -72.17% | -111.75% |
| Income Tax Expenses | 244.44% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.23% | -32.65% | -95.46% | -72.43% | -111.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.23% | -32.65% | -95.46% | -72.43% | -111.81% |
| EBIT | -2.87% | -21.46% | -65.82% | -65.25% | -104.23% |
| EBITDA | -2.43% | -20.86% | -65.05% | -64.84% | -- |
| EPS Basic | 12.26% | -28.18% | -89.04% | -48.69% | -79.03% |
| Normalized Basic EPS | 12.32% | -28.07% | -88.82% | -48.46% | -78.97% |
| EPS Diluted | 12.26% | -28.18% | -89.04% | -48.69% | -79.03% |
| Normalized Diluted EPS | 12.32% | -28.07% | -88.82% | -48.46% | -78.97% |
| Average Basic Shares Outstanding | 17.66% | 3.48% | 3.39% | 15.95% | 18.30% |
| Average Diluted Shares Outstanding | 17.66% | 3.48% | 3.39% | 15.95% | 18.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |